Showing results (601-610 of 670) with videos related to

Sort By:
Pageof 67
EMBO Reports|February 14, 2022
Targeting human CALR-mutated MPN progenitors with a neoepitope-directed monoclonal antibodyDenis Tvorogov, Chloe A L Thompson-Peach, Johannes Foßelteder, et al.
Cancer Discovery|November 10, 2022
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal VulnerabilityDaniel Thomas, Manhong Wu, Yusuke Nakauchi, et al.
Plos One|September 19, 2024
CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targetingKelly Lim, Winnie L Kan, Pramod C Nair, et al.
Euro Surveillance : Bulletin Europeen Sur Les Maladies Transmissibles = European Communicable Disease Bulletin|July 15, 2022
Epidemiological and microbiological investigation of a large increase in vibriosis, northern Europe, 2018Ettore Amato, Maximilian Riess, Daniel Thomas-Lopez, et al.
Circulation. Cardiovascular Interventions|October 17, 2013
Cognitive trajectory after transcatheter aortic valve implantationAlexander Ghanem, Justine Kocurek, Jan-Malte Sinning, et al.
Leukemia|August 29, 2022
A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposureMonika M Kutyna, Chung Hoow Kok, Yoon Lim, et al.
Genes, Chromosomes & Cancer|February 19, 2026
IRF2BP2::JAK2 Defines a Novel Kinase-Activating Fusion in Pediatric T-Cell Acute Lymphoblastic LeukemiaFatimah B Jalud, Tasnia Ibnat, Kaitlyn Kew, et al.
Cell Stem Cell|November 27, 2015
Leukemia-Associated Cohesin Mutants Dominantly Enforce Stem Cell Programs and Impair Human Hematopoietic Progenitor DifferentiationClaire Mazumdar, Ying Shen, Seethu Xavy, et al.
Cancers|August 26, 2023
A Personalized Risk Model for Azacitidine Outcome in Myelodysplastic Syndrome and Other Myeloid Neoplasms Identified by Machine Learning Model Utilizing Real-World DataKirsty Sharplin, William Proudman, Rakchha Chhetri, et al.
Clinical and Translational Science|July 23, 2022
First-in-human, randomized, double-blind, placebo-controlled, dose escalation trial of the anti-herpes simplex virus monoclonal antibody HDIT101 in healthy volunteersAntje Blank, Nicolas Hohmann, Marlen Dettmer, et al.
Pageof 67